for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Knight Therapeutics Inc

GUD.TO

Latest Trade

5.02CAD

Change

-0.15(-2.90%)

Volume

696,990

Today's Range

4.99

 - 

5.18

52 Week Range

4.73

 - 

8.08

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Knight Announces Filing Of Preliminary Base Shelf Prospectus

Dec 10 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT ANNOUNCES FILING OF PRELIMINARY BASE SHELF PROSPECTUS.KNIGHT THERAPEUTICS - FILED PRELIMINARY SHORT FORM BASE SHELF PROSPECTUS TO OFFER FOR SALE AND ISSUE UP TO $360 MILLION OF COMMON SHARES.KNIGHT THERAPEUTICS - FILED PRELIM SHORT FORM BASE SHELF PROSPECTUS TO OFFER FOR SALE, ISSUE UP TO $360 MILLION OF SUBSCRIPTION RECEIPTS, DEBT SECURITIES.

Knight Therapeutics Reports Third Quarter 2020 Results

Nov 13 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS REPORTS THIRD QUARTER 2020 RESULTS.KNIGHT THERAPEUTICS INC - QTRLY REVENUES C$45.2 MILLION VERSUS C$4 MILLION.KNIGHT THERAPEUTICS INC - QTRLY BASIC EARNINGS PER SHARE C$0.14.

Knight Therapeutics Announces Filling Of Supplement To A New Drug Submission For Nerlynx®

Sept 3 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS ANNOUNCES FILLING OF SUPPLEMENT TO A NEW DRUG SUBMISSION FOR NERLYNX® (NERATINIB) TO TREAT HER2-POSITIVE METASTATIC BREAST CANCER.KNIGHT THERAPEUTICS INC - SNDS FOR NERLYNX IS SUPPORTED BY RESULTS OF PHASE III NALA TRIAL.

Knight Therapeutics Inc - Qtrly Revenue $53.3 Million

Aug 13 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS REPORTS SECOND QUARTER 2020 RESULTS.QTRLY REVENUE $53.3 MILLION.Q2 REVENUE VIEW C$50.8 MILLION -- REFINITIV IBES DATA.QTRLY EARNINGS PER SHARE $0.13.Q2 EARNINGS PER SHARE VIEW C$-0.03 -- REFINITIV IBES DATA.ALL CURRENCIES ARE CANADIAN.

Knight Announces Normal Course Issuer Bid

July 10 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT ANNOUNCES NORMAL COURSE ISSUER BID.KNIGHT THERAPEUTICS - PROPOSES TO PURCHASE, FROM TIME TO TIME OVER NEXT 12 MONTHS, IF CONSIDERED ADVISABLE, UP TO 10.9 MILLION COMMON SHARES OF CO.

Knight Therapeutics Inc - QTRLY Basic Net Loss Per Share $0.01

Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS REPORTS FIRST QUARTER 2020 RESULTS.KNIGHT THERAPEUTICS INC - QTRLY BASIC NET LOSS PER SHARE $0.01.

Knight Therapeutics Reports Q4 Loss Per Share Of $0.049

March 30 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END 2019 RESULTS.KNIGHT THERAPEUTICS - QTRLY LOSS PER SHARE $0.049.

Knight Therapeutics Inc Says Co, Medison Biotech (1995) Ltd Have Agreed To Separate Their Businesses

Nov 21 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS INC - CO, MEDISON BIOTECH (1995) LTD HAVE AGREED TO SEPARATE THEIR BUSINESSES.KNIGHT THERAPEUTICS - KNIGHT WILL SELL TO MEDISON GROUP ALL OF KNIGHT'S SHARES IN MEDISON, REFLECTING APPROXIMATELY 28.3% OF SHARE CAPITAL OF MEDISON.KNIGHT THERAPEUTICS INC - KNIGHT WILL SELL TO MEDISON GROUP ALL OF KNIGHT'S SHARES IN MEDISON IN CONSIDERATION FOR C$77 MILLION PAYABLE IN CASH.KNIGHT THERAPEUTICS INC - CO, MEDISON AGREED TO RELEASE EACH OTHER FROM ALL CLAIMS AND WITHDRAW ALL LEGAL PROCEEDINGS INITIATED BY BOTH PARTIES.KNIGHT THERAPEUTICS INC - MEDISON AGREED TO A FOUR-YEAR STANDSTILL COMMITMENT AND WILL DIVEST ITS POSITION IN KNIGHT DURING THE FOUR-YEAR PERIOD.KNIGHT THERAPEUTICS INC - MEDISON, TOGETHER WITH ITS AFFILIATES OWN ABOUT 10.4 MILLION SHARES OR 7.5% OF KNIGHT.

Knight Therapeutics Inc- QTRLY Revenue C$4 Million Versus C$ 3.2 Million

Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS REPORTS THIRD QUARTER 2019 RESULTS.QTRLY LOSS PER SHARE C$0.021.QTRLY REVENUE C$4 MILLION VERSUS C$ 3.2 MILLION.Q3 EARNINGS PER SHARE VIEW C$0.03, REVENUE VIEW C$3.4 MILLION -- REFINITIV IBES DATA.

Brazil's Biotoscana Appoints Claudio Coracini As Interim CEO After Agreement To Sell Control To Knight Therapeutics- Filing

Oct 28 (Reuters) - Biotoscana Investments SA <GBIO33.SA>::BRAZIL'S BIOTOSCANA APPOINTS CLAUDIO CORACINI AS INTERIM CEO AFTER AGREEMENT TO SELL CONTROL TO KNIGHT THERAPEUTICS- FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up